

DIVI'S LABORATORIES LIMITED

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER, 2007 (Rs.in Lakhs)

	Particulars	STANDALONE				
		Quarter ended 30.09.2007	Quarter Ended 30.09.2006	Period ended 30.09.2007	Period ended 30.09.2006	Year Ended 31.03.2007
		Unaudited	Unaudited	Unaudited	Unaudited	Audited
	(1)	(2)	(3)	(4)	(5)	(6)
1	Net Sales/Income from operations (Net of Excise Duty)	24251	16137	47058	32221	72442
2	Other Income	154	340	498	776	1361
3	<u>Total Income:</u>	24405	16477	47556	32997	73803
4	<u>Expenditure:</u>					
	a. (Increase) / Decrease in Stock-in-Trade and Work-in-Progress	(2118)	931	(2741)	1368	1198
	b. Consumption of Raw Material	10883	7525	21596	15283	31112
	e. Purchase of Traded Goods	0	0	0	0	0
	d. Staff Cost	1212	1028	2360	1992	5158
	e. Depreciation	782	415	1643	842	2233
	e. Other Expenditure					
	- Manufacturing Expenses	1659	959	3075	1893	4381
	- Other expenses	2114	1345	3841	2729	5994
	Total	14532	12204	29774	24107	50076
5	Finance charges	315	65	652	270	1057
6	Exceptional items	0	0	0	0	0
7	<u>Profit from ordinary activities before Tax (3-4+5+6)</u>	9558	4209	17130	8620	22670
8	Tax Expense					
	- Current Tax	5	1140	490	2810	3332
	- Deferred Tax	423	(63)	778	0	137
	- Fringe Benefit Tax	5	4	9	7	27
9	<u>Net Profit from ordinary activities after Tax: (7-8)</u>	9125	3128	15853	5803	19174
10	Extra-ordinary items (net of tax expense)	0	0	0	0	0
11	Net Profit (+)/Loss(-) for the period (9-10)	9125	3129	15853	5803	19174
12	Paid-up Equity Share Capital (Face Value: Rs.2 each)	1291	1282	1291	1282	1291
13	Reserves excluding revaluation reserves					52913
14	Earnings per Share					

a)	Basic Earnings Per Share before extra-ordinary items	Rs.	14.13	4.88	24.56	9.05	29.91
	Diluted Earnings Per Share before extra-ordinary items	Rs.	13.97	4.79	24.28	8.88	29.55
b)	Basic Earnings Per Share after extra-ordinary items	Rs.	14.13	4.88	24.56	9.05	29.91
	Diluted Earnings Per Share after extra-ordinary items	Rs.	13.97	4.79	24.28	8.88	29.55
14	Aggregate of public shareholding:						
	- No. of shares		29992600	29528500	29992600	29528500	29992100
	- % of shareholding		46.46%	46.07%	46.46%	46.07%	46.46%

NOTES:

1. The above results for the Quarter ended 30th September 2007, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 27th October, 2007.
2. The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates. Accordingly there are no reportable segments as per Accounting Standard 17 on Segment Reporting issued by the Institute of Chartered Accountants of India.
3. The figures for the previous year/period have been regrouped, wherever necessary.
4. Consequent to split of equity shares to a face value of Rs.2/- each, number of shares and EPS has been reworked for the previous periods in conformity with the current quarter.
5. Consolidated Financial Results of the company with its subsidiaries M/s.Divis Laboratories (USA) Inc and M/s.Divi's Laboratories Europe AG are given below:

		Rs.lakhs				
	Particulars	Quarter ended 30.09.2007	Quarter ended 30.09.2006	Period ended 30.09.2007	Period ended 30.09.2006	Year Ended 31.03.2007
1	Turnover	24384	16172	47056	32241	72458
2	Net Profit after tax	9097	2990	15586	5554	18586
3	Earnings Per Share (Face Value Rs.2 each)					
	Basic: Rs.	14.09	4.67	24.14	8.67	28.79
	Diluted: Rs.	13.93	4.58	23.87	8.50	28.65

6. Details of Investor complaints pursuant to Clause 41 of the Listing Agreement for the quarter ended 30.09.2007:

Opening: Nil, Received during the Quarter: 10, Resolved: 10, Closing: Nil

for Divi's Laboratories Limited

Place: Hyderabad
Date: 27th October, 2007

Dr. Murali K. Divi
Chairman & Managing Director